UPDATE: UBS Upgrades MedAssets (MDAS) to Buy; RCM Growth To Accelerate
Tweet Send to a FriendGet Alerts MDAS Hot Sheet
Price: $17.73 -0.51%
Rating Summary:
11 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 13
Rating Summary:
11 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 28 | New: 13
Trade MDAS Now!
(Updated - June 21, 2012 11:41 AM EDT)
UBS upgraded MedAssets (NASDAQ: MDAS) from Neutral to Buy. PT raised from $14 to $18.
Analyst, Stephen Shankman, said, "In our view, MDAS’ Revenue Cycle Management (RCM) segment is set up to outperform in 2012 (vs. guidance) and RCM growth should accelerate over the next few years. We believe MDAS will benefit from increasing demand for RCM (including consulting) leveraged by recent internal operational changes. As such, we see the combination of accelerating momentum in the RCM segment combined with ongoing solid SCM execution helping drive the PE multiple toward our ~15% LT EPS growth rate."
For an analyst ratings summary and ratings history on MedAssets click here. For more ratings news on MedAssets click here.
Shares of MedAssets closed at $12.72 yesterday, with a 52 week range of $8.52-$14.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS upgraded MedAssets (NASDAQ: MDAS) from Neutral to Buy. PT raised from $14 to $18.
Analyst, Stephen Shankman, said, "In our view, MDAS’ Revenue Cycle Management (RCM) segment is set up to outperform in 2012 (vs. guidance) and RCM growth should accelerate over the next few years. We believe MDAS will benefit from increasing demand for RCM (including consulting) leveraged by recent internal operational changes. As such, we see the combination of accelerating momentum in the RCM segment combined with ongoing solid SCM execution helping drive the PE multiple toward our ~15% LT EPS growth rate."
For an analyst ratings summary and ratings history on MedAssets click here. For more ratings news on MedAssets click here.
Shares of MedAssets closed at $12.72 yesterday, with a 52 week range of $8.52-$14.58.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
